John Brennan
Psychiatry · Dallas, TXNPI 1336123173
Payments from drug & device makers
Across 1,097 payments — averaging $17.52 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Bausch Health US, LLC$2K
- Validus Pharmaceuticals LLC$2K
- Otsuka America Pharmaceutical, Inc.$2K
- ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.)$1K
- Lundbeck LLC$1K
- AbbVie$1K
- plus $10K from 30 others
What the payments were for
- Consulting fees$5503%
- Food & beverage$18,55997%
- Education$1121%
- Gifts$20%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- Equetro$1,273
- Adzenys XR-ODT$675
- Cotempla XR-ODT$675
- QELBREE$298
- Quillichew ER$125
- Dyanavel XR$125
- Quillivant$125
- VRAYLAR$117
How this compares
$19,223 in reported general payments places this provider in the 90th percentile of 2,238 psychiatry providers in Texas.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| CaplytaLumateperone Tosylate | 29 | $67,887 |
| RexultiBrexpiprazole | 29 | $64,580 |
| NuedextaDextromethorphan Hbr/Quinidine | 22 | $34,498 |
| LybalviOlanzapine/Samidorphan Malate | 20 | $31,870 |
| TrintellixVortioxetine Hydrobromide | 12 | $11,560 |
| Dextroamphetamine-AmphetamineDextroamphetamine/Amphetamine | 267 | $9,880 |
| BelsomraSuvorexant | 14 | $8,954 |
| CymbaltaDuloxetine Hcl | 12 | $6,620 |
| Venlafaxine Hcl ErVenlafaxine Hcl | 196 | $5,468 |
| Desvenlafaxine Succinate ErDesvenlafaxine Succinate | 81 | $5,059 |
| Duloxetine Hcl | 101 | $4,660 |
| DayvigoLemborexant | 13 | $4,275 |
| Bupropion XlBupropion Hcl | 96 | $3,720 |
| Trazodone Hcl | 241 | $2,675 |
| Clonazepam | 339 | $1,822 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.)Caplyta | $1,305 | $67,88729 claims |
| Otsuka America Pharmaceutical, Inc.Rexulti | $1,586 | $64,58029 claims |
| Avanir Pharmaceuticals, Inc.Nuedexta | $693 | $34,49822 claims |
| Alkermes, Inc.Lybalvi | $840 | $31,87020 claims |
| Takeda Pharmaceuticals U.S.A., Inc.Trintellix | $951 | $11,56012 claims |
| MerckBelsomra | $147 | $8,95414 claims |
| Eisai Inc.Dayvigo | $305 | $4,27513 claims |
| Almatica Pharma LLCSertraline Hcl | $1,052 | $52322 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 90th percentile of 2,238 psychiatry providers in Texas.
Other psychiatry in Dallas
- Scott BartleyDallas$42.7M
- Darin OkudaDallas$14.7M
- Michael DowningDallas$7.6M
- John PascoeDallas$2.3M
- Madhukar TrivediDallas$2.1M
- Manish JhaDallas$1.3M
- Mary KnesevichDallas$1.2M
- Seema GuptaDallas$1.2M
- Eric WilliamsDallas$976K
- Joel HolinerDallas$948K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.